



Videoconference – December 19, 2023

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) **the ability of its products** to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this presentation relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 28, 2022, (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 24 of the Universal Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This presentation is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this presentation does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this presentation may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this presentation are encouraged to inquire about, and required to comply with, these restrictions.

All information in the presentation speaks only as of (1) the date hereof, in the case of information about the Company and (2) the date of such information, in the case of information from persons other than the Company. The Company does not undertake any duty to update or revise the information contained herein, publicly or otherwise. The Company has not independently verified any third-party information and makes no representation as to the accuracy or completeness of any such information.



Videoconference – December 19, 2023

UZEDY™



Successful commercial launch by Teva

First royalties received by MedinCell



Videoconference – December 19, 2023

mdc-TJK

Once-monthly olanzapine for schizophrenia

Acceleration of ongoing Phase 3

Results now expected in the second half of 2024

May be the first long-acting injectable olanzapine product with a favorable safety profile





STRONG DIFFERENTIATION THANKS TO BEPO®

Subcutaneous injection

Prefilled syringe

Immediate onset of action

Desirable pharmacokinetics



Videoconference – December 19, 2023

mdc-TJK

Once-monthly olanzapine for schizophrenia

As of November 29, 2023:

Over 600 patients (out of 640) recruited
no post-injection delirium/sedation syndrome
(PDSS) had been observed on over 1400 injections

Study's primary endpoints
and first safety data in H2 2024



mdc-CWM

celecoxib - postoperative pain

Recruitment completed in August (151 patients)

**Last patient completing the 3 month follow-up
period end of November 2023**

**Data base lock and topline results
are expected in the first quarter of 2024**



Videoconference – December 19, 2023

Half-Year Financials

Income from ordinary activities: €8.2 million

+6.1% vs. first half of previous year,
of which €7.0 million in revenue, +15.9%

Operating expenses: €17.1 million

-11.5% vs. first half of previous year

Net income: €-8.2 million



Half-Year Financials

Available cash: €26.8 million

of which 15.0 M€ in non-risky current financial assets

Main cash payments received after the closing

+€4.2 million from the 2022 Research Tax Credit

+€2.6 million from the Gates Foundation for
collaboration on the mdc-WWM program



Q&A



Videoconference – December 19, 2023